218 related articles for article (PubMed ID: 26772427)
1. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
Zhang RX; Cai P; Zhang T; Chen K; Li J; Cheng J; Pang KS; Adissu HA; Rauth AM; Wu XY
Nanomedicine; 2016 Jul; 12(5):1279-90. PubMed ID: 26772427
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
3. Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Zhang RX; Zhang T; Chen K; Cheng J; Lai P; Rauth AM; Pang KS; Wu XY
J Vis Exp; 2017 Oct; (128):. PubMed ID: 29053672
[TBL] [Abstract][Full Text] [Related]
4. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.
Prasad P; Shuhendler A; Cai P; Rauth AM; Wu XY
Cancer Lett; 2013 Jul; 334(2):263-73. PubMed ID: 22902994
[TBL] [Abstract][Full Text] [Related]
7. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
8. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Shuhendler AJ; Prasad P; Zhang RX; Amini MA; Sun M; Liu PP; Bristow RG; Rauth AM; Wu XY
Mol Pharm; 2014 Aug; 11(8):2659-74. PubMed ID: 24830351
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
10. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
12. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
13. Alternating block copolymer-based nanoparticles as tools to modulate the loading of multiple chemotherapeutics and imaging probes.
Mattu C; Brachi G; Menichetti L; Flori A; Armanetti P; Ranzato E; Martinotti S; Nizzero S; Ferrari M; Ciardelli G
Acta Biomater; 2018 Oct; 80():341-351. PubMed ID: 30236799
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
15. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
17. Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.
Yu C; Zhou M; Zhang X; Wei W; Chen X; Zhang X
Nanoscale; 2015 Mar; 7(13):5683-90. PubMed ID: 25740312
[TBL] [Abstract][Full Text] [Related]
18. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
[TBL] [Abstract][Full Text] [Related]
19. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
20. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
